Home » Newsletters » BioWorld Science

BioWorld Science

Feb. 24, 2000

View Archived Issues

Corixa subscribes to Incyte's LifeSeq Gold database

Telomerase gene therapy may offer potential liver cirrhosis therapy

Myriad Genetics advances drug discovery programs during second quarter

Anti-tat gene therapy blocks HIV replication, may offer new treatment alternative

Altus receives funding for GI lipase enzyme therapy

YM-872 exerts neuroprotective effects in rat transient MCA occlusion model

Human Genome Sciences moves three drugs into clinical development in 1999

SkyePharma achieves positive phase II results for DepoMorphine; DepoCyt approved in Canada

GenVec licenses gene for treating blindness

New study contradicts earlier indications of efficacy for ERT in treating Alzheimer's disease

Elan/Endorex joint venture to develop iron-chelating products with Schein

Modified oligonucleotides with staggered PS/PO linkages designed at Isis

CAN-296 may inhibit fungal ATPase-mediated proton pumping

Synaptic discovers potent and selective human alpha1D-adrenoceptor antagonists

Study disproves earlier reports of serious treatment-related side effect of deferiprone

NPY Y1-selective compounds for diagnostic, therapeutic use available for licensing

Compounds activating PPAR isoforms described by Merck for lipid disorders, diabetes

Salk team identifies potential target for the elusive male contraceptive

Orally active antiplatelet agents in development at Lafon

Merck presents new nonpeptide GnRH antagonists

Immune Response's mbGM-CSF vaccine offers protection against melanoma

Pregabalin now claimed for renal colic-associated pain

Ono claims selective EP4 receptor ligands and their use

New treatment for COPD from Ono to enter clinical trials soon

AMPA antagonists improve neurological outcome in EAE

Nastech's NDA for intranasal scopolamine not accepted for filing

Remicade recommended for approval in E.U. for treatment of rheumatoid arthritis

FDA issues approvable letter for Pharmacia & Upjohn's Vestra